Conference Day Two

9:00 am Coffee & Light Breakfast

9:25 am Chair’s Opening Remarks

  • Debanjan Das Senior Associate Director & Science Fellow, Global R&D, Bayer

Translational Modelling for Nasal Drug Delivery to Maximize Practical Drug Applications

9:30 am Quantifying Intranasal Nose to Brain Cell Secretome Delivery to Non-Human Primates and Clinical Translation From Preclinical to Clinical Settings

  • Larry Brown Executive Vice President & Chief Scientific Officer, Noveome Biotherapeutics

Synopsis

  • Quantifying labeled protein techniques to measure drug distribution with biomarker analyses and exploring the therapeutic effect of intranasal delivery in human subjects
  • Discussion of the critical regulatory pathways and methodologies that bridge preclinical findings to clinical applications
  • Clinical case study presentation demonstrating targeted intranasal nose to brain delivery, highlighting key results, challenges faced, and lessons learned

10:00 am Effects of Particulate Matter in Unit Dose Nasal Spray Devices on Spray Performance and Mitigation Strategies for Manufacturing

Synopsis

  • Potential types of particulate matter in nasal spray drug products
  • Impact of particulate matter on spray performance
  • Mitigation of Finished Product particulates in Manufacturing of nasal sprays

10:30 am Assessing Nasal Drug Delivery in Humans: Bridging Preclinical Insights to Clinical Applications

  • Krishna Subramanian Vice President, Head of Non-clinical & Translational Science, Seelos Therapeutics

Synopsis

  • Examining cutting-edge imaging techniques and biomarker analysis for evaluating drug distribution and nasal delivery efficacy in humans
  • Discussing essential methodologies and pathways that connect preclinical evidence to clinical trial outcomes
  • Reviewing case studies showcasing successful nasal drug delivery, focusing on key findings, challenges, and practical takeaways

11:00 am Break & Networking

11:30 am The Development of Novel Spray-Dried Intranasal Neurosteroids for the Treatment of Neurological Disease

Synopsis

  • Spray-dried powder formulation development of neurosteroid enantiomers
  • Novel intranasal device performance with spray-dried neurosteroids
  • Phase I clinical trial results following treatment of concussive brain injury with intranasal device: neurosteroid combination

12:00 pm Transnasal Minimally Invasive Trigeminal Interventions

  • Marc Dean Physcian, Otologic Research Institute
  • Joe Krespi Director, Hofstra University Medical School, Lenox Hill Hospital, NYC

Synopsis

  • Trigeminal nerve pathways and their anatomical connections to the brain, highlighting how nasal drug delivery can leverage these routes for targeted delivery
  • Combination of Radiologic and Endoscopic Video assisted Large Language Models (AI) to maximize the efficacy of N2B drug delivery
  • Current research and clinical applications utilizing trigeminal nerve, NALT, Eustachian Tube pathways for drug delivery, emphasizing their potential in enhancing therapeutic outcomes

12:30 pm Lunch Break & Networking

Determining the Efficacy of Delivery Devices to Improve Target Region Delivery

1:30 pm Selecting the Optimal Delivery Device: Options, Challenges and Opportunities (Or a “Shopping List” to Consider)

Synopsis

  • A increasing range of delivery technology is available for purchase or partnering representing a portfolio of options for the drug developer
  • Systematic review of the product development needs, careful definition of key project-specific selection criteria and robust matching with the attributes and limitations of different systems is essential
  • Significant opportunities can be realized through such a judicious approach to the combination of drug and formulation with the optimal delivery device

2:00 pm Roundtable: Innovations and Challenges in Mucoadhesive Systems for Nasal Drug Delivery

  • Debanjan Das Senior Associate Director & Science Fellow, Global R&D, Bayer

Synopsis

  • Discussing advancements in mucoadhesive technologies to enhance nasal drug retention and absorption
  • Identifying challenges related to formulation, adhesion, and patient tolerability
  • Exploring regulatory considerations and testing methods for mucoadhesive-based nasal formulations

2:30 pm Designing Modified Release Formulations for Nasal Administration of Local, Systemic and Targeted Drug Molecules

  • Debanjan Das Senior Associate Director & Science Fellow, Global R&D, Bayer

Synopsis

  • Consideration of critical formulation parameters to design modified release (immediate & delayed) dosage forms
  • Evaluation of spray characteristics for targeted deposition in internal nasal structures
  • Development of in vitro nasal permeation models with PAMPA & other artificial membranes for enhanced delivery
  • Formulation attributes to enhance enhanced absorption for N2B delivery in olfactory region

3:00 pm Chair’s Closing Remarks

  • Debanjan Das Senior Associate Director & Science Fellow, Global R&D, Bayer